Cargando…

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry

The objective of this study was to compare rheumatoid arthritis (RA) disease activity and patient-reported outcomes (PROs) in a national sample of patients with RA with/without Sjögren’s syndrome (SS). Adults with RA from a large observational US registry (Corrona RA) with known SS status between 22...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrold, Leslie R., Shan, Ying, Rebello, Sabrina, Kramer, Neil, Connolly, Sean E., Alemao, Evo, Kelly, Sheila, Kremer, Joel M., Rosenstein, Elliot D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Observational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316680/ https://www.ncbi.nlm.nih.gov/pubmed/32449040 http://dx.doi.org/10.1007/s00296-020-04602-8

Ejemplares similares

Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2020)

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2019)

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?
por: Harrold, Leslie R., et al.
Publicado: (2017)

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept
por: Gossec, Laure, et al.
Publicado: (2017)

Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas’ Inflammatory Bowel Disease Registry
por: Cross, Raymond K, et al.
Publicado: (2022)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis
por: Migliore, Alberto, et al.
Publicado: (2021)

Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease‐Modifying Antirheumatic Drugs: Results From a Real‐World Study
por: Alemao, Evo, et al.
Publicado: (2020)

Malignancy validation in a United States registry of rheumatoid arthritis patients
por: Fisher, Mark C, et al.
Publicado: (2012)

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA
por: Harrold, Leslie R., et al.
Publicado: (2021)

The impact of the COVID-19 pandemic on patients with primary Sjögren syndrome
por: Serban, Augustin, et al.
Publicado: (2021)

Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort
por: Ahmad, Harris A., et al.
Publicado: (2018)

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
por: Fleischmann, Roy, et al.
Publicado: (2019)

Smoking, disease characteristics and serum cytokine levels in patients with primary Sjögren’s syndrome
por: Olsson, Peter, et al.
Publicado: (2018)

Factors associated with severe dry eye in primary Sjögren’s syndrome diagnosed patients
por: Fernandez Castro, Mónica, et al.
Publicado: (2018)

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry
por: Mease, Philip J., et al.
Publicado: (2021)

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Respiratory symptoms are poor predictors of concomitant chronic obstructive pulmonary disease in patients with primary Sjögren’s syndrome
por: Strevens Bolmgren, Victor, et al.
Publicado: (2017)

Peripheral neuropathy and health-related quality of life in patients with primary Sjögren’s syndrome: a preliminary report
por: Jaskólska, Marta, et al.
Publicado: (2020)

Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach
por: Feldman, Candace H., et al.
Publicado: (2019)

Is it possible to not perform salivary gland biopsy in targeted patients according to unstimulated salivary flow results in patients with suspected Sjögren's syndrome?
por: Sebastian, Agata, et al.
Publicado: (2021)

The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry
por: Skácelová, Martina, et al.
Publicado: (2022)

Physical activity but not sedentary activity is reduced in primary Sjögren’s syndrome
por: Ng, Wan-Fai, et al.
Publicado: (2016)

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
por: Harrold, Leslie R., et al.
Publicado: (2018)

Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus
por: Heijke, Rebecca, et al.
Publicado: (2020)

Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey
por: Pappas, Dimitrios A., et al.
Publicado: (2022)

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial
por: DeVore, Adam D., et al.
Publicado: (2018)

Association of latitude and altitude with adverse outcomes in patients with COVID-19: The VIRUS registry
por: Tekin, Aysun, et al.
Publicado: (2022)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry
por: Li, Jing, et al.
Publicado: (2021)

Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data
por: Goss Sawhney, Tia, et al.
Publicado: (2023)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
por: Strand, Vibeke, et al.
Publicado: (2018)

Determinants of Medicare All-Cause Costs Among Elderly Patients with Renal Cell Carcinoma
por: Hollenbeak, Christopher S., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3iom6in2i50n7tln0v4hkm4u6r